Foley & Lardner LLP represented Boston-based health care analytics company Panalgo in its recent agreement to be acquired by Managed Markets Insight & Technology (MMIT) and Evaluate – which joined forces in August to become a $1.6 billion global pharmaceutical commercial intelligence provider.
With the acquisition of Panalgo, MMIT/Evaluate aims to transform the process of bringing life-saving therapies to market. By incorporating Panalgo’s flagship Instant Health Data (IHD) software, MMIT/Evaluate plans to offer customers an end-to-end commercialization platform that provides critical, data-driven insights instantly, allowing life sciences leaders to make better decisions faster.
Founded in 1996, Panalgo has more than 25 years of experience applying health care acumen to build flexible, intuitive, and purpose-built analytics software used by the largest biopharmaceutical, medical device, and contract research organizations around the globe. Panalgo will continue to operate under its own brand. Chief Technology Officer Jordan Menzin will become Panalgo CEO, and Panalgo CEO Joseph Menzin will transition to executive chairman. Both roles are effective on November 1.
The Foley team was led by partner David Kantaros and senior counsel Alex Miska, and included partners Christopher Swift, Jim Nicholas, Dan Rose, Chanley Howell, Raj Tanden, Greg Neppl, Aaron Tantleff, and Casey Knapp, senior counsel Josh Roling, special counsels Marina Choundas and Isaac Morris, and associates Anna Choi, Laura Burlot, Ashley May, William McCaughey, Jordan Bergmann, and Kelsey O’Gorman.